Totect Related Published Studies
Well-designed clinical trials related to Totect (Dexrazoxane)
Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. [2008.03.01]
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. [2007.02.10]
Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. [2006.04]
Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. [2005.12]
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. [2004.07.08]
Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects. [2002.07.01]
Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC). [1999.01]
Dexrazoxane cardioprotection in advanced breast cancer patients undergoing high-dose epirubicin treatment. [1998.01]
Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. [1998.01]
Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. [1997.04]
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. [1996.12]
Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation. [1996.11]
Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy. [1994.08]
Well-designed clinical trials possibly related to Totect (Dexrazoxane)
Irradiation with and without Razoxane in the Treatment of Incompletely Resected or Inoperable Recurrent Rectal Cancer : Results of a Small Randomized Multicenter Study. [2007.07]
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. [2007.02.01]
Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. [2006.02]
Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients. [2000.01]
Radiotherapy vs. radiotherapy and razoxane in the treatment of soft tissue sarcomas: final results of a randomized study. [1996.12.01]
Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. [1996.02]
Peri-operative heparin: a possible adjuvant to surgery in colo-rectal cancer? [1993.07]
Responses of liver metastases to radiotherapy and razoxane. [1992.03]
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. [1992.01]
Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. [1988.09.22]
Other research related to Totect (Dexrazoxane)
Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy. [2008.04]
The use of dexrazoxane for the prevention of anthracycline extravasation injury. [2008.02]
Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience. [2008]
Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo. [2007.12]
Dexrazoxane for anthracycline extravasation. [2007.08]
Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. [2007.07]
Totect: a new agent for treating anthracycline extravasation. [2007.06]
Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. [2007.03]
Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries. [2007]
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? [2007]
Other possibly related research studies
Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo. [2008.07]
Cardioprotective interventions for cancer patients receiving anthracyclines. [2008.04.16]
Chelators controlling metal metabolism and toxicity pathways: applications in cancer prevention, diagnosis and treatment. [2008]
Razoxane and vindesine in advanced soft tissue sarcomas: impact on metastasis, survival and radiation response. [2007.09]
Combined vindesine and razoxane shows antimetastatic activity in advanced soft tissue sarcomas. [2008]
Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer. [2007]
Do antioxidants interfere with radiation therapy for cancer? [2007.09]
Cytoprotective agents used in the treatment of patients with cancer. [2007.08]
Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. [2007.09]
Long-term and short-term models for studying anthracycline cardiotoxicity and protectors. [2007]
Genotyping the risk of anthracycline-induced cardiotoxicity. [2007]
Anthracycline cardiotoxicity in long-term survivors of childhood cancer. [2007]
[Chemotherapeutics-induced heart failure] [2007.07.15]
Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. [2007.07]
Management of anthracycline extravasation injuries. [2007.07]
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. [2007.06]
Evaluation of ECG time intervals in a rabbit model of anthracycline-induced cardiomyopathy: a useful tool for assessment of cardioprotective agents. [2007]
Managing cardiotoxicity in anthracycline-treated breast cancers. [2007.05]
Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. [2007.04.20]
Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, Part 2. [2007.03]
Prevention of anthracycline-induced cardiotoxicity in children: the evidence. [2007.05]
Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. [2007.01]
Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. [2007.01.29]
Long-term effects of treatments for childhood cancers. [2007.02]
Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls. [2007.01]
[The significance of extravasation in oncological care] [2008.03]
|
